News
Public · Published
MIRM: A growing rare-disease portfolio pairs $715M–$720M 2026 sales guidance with key 2027 milestones
Mirum Pharmaceuticals reported that four approved rare-disease medicines generated $521 million in 2025 net product sales. The company guided to $715 million–$720 million in 2026 sales, while reporting that multiple clinical programs met key endpoints and that major submissions and data readouts are planned through 2027.
Published:
Updated:
What happened
Mirum Pharmaceuticals reported that four approved rare-disease medicines generated $521 million in 2025 net product sales. The company guided to $715 million–$720 million in 2026 sales, while reporting that multiple clinical programs met key endpoints and that major submissions and data readouts are planned through 2027.
Confirmed
Global impact / market context
The sales guidance signals that Mirum expects revenue from its approved medicines to grow in 2026. If achieved, that revenue could support research and development spending, while upcoming submissions and trial results may determine whether newer treatments can add future sales; neither outcome is assured.
Analyst inference
The update combines current product revenue with clinical and regulatory milestones, so investors are weighing an operating business against development risk. Trial endpoints are preset measures of success, and submissions are requests for regulatory review; the article gives no specific outcomes beyond those stated.
Analyst inference
What to watch
- Whether 2026 net product sales reach the $715 million–$720 million guidance range, since sales from approved medicines provide revenue that can fund ongoing operations and research. Analyst inference
- Which major regulatory submissions are planned through 2027, and when they are made; a submission starts formal review but does not guarantee approval or sales. Analyst inference
- The timing and results of planned data readouts through 2027, because trial findings can affect the likelihood that clinical programs advance toward regulatory review. Analyst inference
Evidence
- Original source link unavailable